 |
138 Diseases |  |
93 Trials |
|
93 Trials |  |
2194 News |  |
| «12...2122232425262728293031...3334» |
- | tamoxifen / Generic mfg.
New P3 trial: Density Lowering Effect of "OFS Add on to TMX"(DELFINO Trial) (clinicaltrials.gov) - Sep 11, 2018
P3, N=224, Recruiting, Sponsor: Seoul National University Hospital
- ||| leuprolide acetate for depot suspension / Generic mfg.
Trial completion: Special Drug Use Surveillance of Leuprorelin for Injection Kit 22.5 mg in "Premenopausal Breast Cancer" (clinicaltrials.gov) - Sep 10, 2018
P=N/A, N=312, Completed, Sponsor: Takeda
Active, not recruiting --> Completed
- | Xtandi (enzalutamide capsule) / Pfizer, Astellas
Trial primary completion date, Combination therapy: Enzalutamide, Radiation Therapy and Hormone Therapy in Treating Patients With Intermediate or High-Risk Prostate Cancer (clinicaltrials.gov) - Aug 25, 2018
P1, N=25, Active, not recruiting, Sponsor: Sidney Kimmel Cancer Center at Thomas Jefferson University
Active, not recruiting --> Completed Trial primary completion date: Dec 2018 --> Jul 2017
- | leuprolide acetate for depot suspension / Generic mfg.
Trial initiation date: GRAET: GnRH Agonist at Embryo Transfer: IVF Outcomes (clinicaltrials.gov) - Aug 17, 2018
P3, N=442, Not yet recruiting, Sponsor: Maimonides Medical Center
Trial primary completion date: Dec 2018 --> Jul 2017 Initiation date: Jul 2018 --> Oct 2018
- ||| leuprolide acetate for depot suspension / Generic mfg.
New trial: Specified Drug-Use Survey of Leuprorelin Acetate Injection Kit 11.25 mg "All-Case Investigation: Spinal and Bulbar Muscular Atrophy (SBMA)" (clinicaltrials.gov) - Aug 13, 2018
P=N/A, N=300, Recruiting, Sponsor: Takeda
- || leuprolide acetate for depot suspension / Generic mfg.
Trial completion date, Trial primary completion date: CRONOS II: Evaluation of Diet and Exercise in Prostate Cancer Patients (clinicaltrials.gov) - Aug 9, 2018
P=N/A, N=1300, Recruiting, Sponsor: AbbVie
Initiation date: Jul 2018 --> Oct 2018 Trial completion date: Aug 2022 --> Jul 2021 | Trial primary completion date: Aug 2022 --> Jul 2021
- || letrozole / Generic mfg., leuprolide acetate for depot suspension / Generic mfg., everolimus / Generic mfg.
Trial completion date, Trial primary completion date: Study of (1) Everolimus, (2) Estrogen Deprivation Therapy (EDT) With Leuprolide + Letrozole and (3) Everolimus + EDT in Patients With Unresectable Fibrolamellar Hepatocellular Carcinoma (FLL-HCC) (clinicaltrials.gov) - Aug 2, 2018
P2, N=84, Active, not recruiting, Sponsor: Memorial Sloan Kettering Cancer Center
Trial completion date: Aug 2022 --> Jul 2021 | Trial primary completion date: Aug 2022 --> Jul 2021 Trial completion date: Jul 2018 --> Jul 2019 | Trial primary completion date: Jul 2018 --> Jul 2019
- | Herceptin (trastuzumab) / Roche, trastuzumab/pertuzumab (EG13084) / EirGenix, Perjeta (pertuzumab) / Roche
Trial completion date, Trial primary completion date: NEOADAPT: NEOADjuvant Aromatase Inhibitor and Pertuzumab/Trastuzumab for Women With Breast Cancer (clinicaltrials.gov) - Jul 27, 2018
P2, N=32, Recruiting, Sponsor: Midwestern Regional Medical Center
Trial completion date: Jul 2018 --> Jul 2019 | Trial primary completion date: Jul 2018 --> Jul 2019 Trial completion date: Apr 2018 --> Jul 2018 | Trial primary completion date: Apr 2018 --> Jul 2018
- | Erleada (apalutamide) / J&J
Trial primary completion date: Apalutamide Plus Intermittent Hormone Therapy Versus Intermittent Hormone Therapy Alone in Prostate Cancer (clinicaltrials.gov) - Jul 24, 2018
P2, N=66, Not yet recruiting, Sponsor: Robert J Amato
Trial completion date: Apr 2018 --> Jul 2018 | Trial primary completion date: Apr 2018 --> Jul 2018 Trial primary completion date: Jul 2022 --> Dec 2022
- | leuprolide acetate for depot suspension / Generic mfg.
Enrollment change, Trial completion date, Trial withdrawal, Trial primary completion date: Effect of Short Term Ovarian Suppression on Androgen Overproduction in Overweight Girls With Androgen Excess (clinicaltrials.gov) - Jul 19, 2018
P1, N=0, Withdrawn, Sponsor: University of Virginia
Trial primary completion date: Jul 2022 --> Dec 2022 N=20 --> 0 | Trial completion date: Jun 2020 --> Jul 2018 | Not yet recruiting --> Withdrawn | Trial primary completion date: Jun 2019 --> Jul 2018
- | leuprolide acetate for depot suspension / Generic mfg.
Trial primary completion date: Pilot Study of Leuprolide to Improve Immune Function After Allogeneic Bone Marrow Transplantation (clinicaltrials.gov) - Jul 18, 2018
P2, N=76, Active, not recruiting, Sponsor: National Cancer Institute (NCI)
N=20 --> 0 | Trial completion date: Jun 2020 --> Jul 2018 | Not yet recruiting --> Withdrawn | Trial primary completion date: Jun 2019 --> Jul 2018 Trial primary completion date: Nov 2020 --> Dec 2017
- | Keytruda (pembrolizumab) / Merck (MSD), nelitolimod (SD-101) / TriSalus Life Sci, UT MD Anderson Cancer Center
Enrollment open, PD(L)-1 Biomarker: Pembrolizumab +/- SD-101 in Hormone-Na (clinicaltrials.gov) - Jul 18, 2018
P2, N=42, Recruiting, Sponsor: Lawrence Fong
Trial primary completion date: Nov 2020 --> Dec 2017 Suspended --> Recruiting
- | goserelin acetate / Generic mfg., leuprolide acetate for depot suspension / Generic mfg., docetaxel / Generic mfg.
Trial primary completion date, Surgery: CALGB 90203: Surgery With or Without Docetaxel and Leuprolide or Goserelin in Treating Patients With High-Risk Localized Prostate Cancer (clinicaltrials.gov) - Jul 10, 2018
P3, N=788, Active, not recruiting, Sponsor: Alliance for Clinical Trials in Oncology
Suspended --> Recruiting Trial primary completion date: Jun 2018 --> Oct 2018
- | Vesanoid (tretinoin) / Roche
New P2 trial: A Pilot Study of 5-AZA and ATRA for Prostate Cancer With PSA-only Recurrence After Local Treatment (clinicaltrials.gov) - Jun 27, 2018
P2, N=20, Recruiting, Sponsor: Icahn School of Medicine at Mount Sinai
- || leuprolide acetate for depot suspension / Generic mfg.
Enrollment change, Trial completion date, Trial primary completion date: CRONOS II: Evaluation of Diet and Exercise in Prostate Cancer Patients (clinicaltrials.gov) - Jun 21, 2018
P=N/A, N=1300, Recruiting, Sponsor: AbbVie
Trial primary completion date: Jun 2018 --> Oct 2018 N=860 --> 1300 | Trial completion date: Jul 2021 --> Aug 2022 | Trial primary completion date: Jul 2021 --> Aug 2022
- || Trial completion: Exisulind and Intermittent Androgen Suppression (ADT) in Biochemical Relapsed Prostate Cancer (clinicaltrials.gov) - Jun 3, 2018
P2, N=32, Completed, Sponsor: University of Washington
N=860 --> 1300 | Trial completion date: Jul 2021 --> Aug 2022 | Trial primary completion date: Jul 2021 --> Aug 2022 Active, not recruiting --> Completed
- | leuprolide acetate for depot suspension / Generic mfg.
New P3 trial: GRAET: GnRH Agonist at Embryo Transfer: IVF Outcomes (clinicaltrials.gov) - Jun 2, 2018
P3, N=442, Not yet recruiting, Sponsor: Maimonides Medical Center
- || Kepivance (palifermin) / SOBI, Amgen, Firmagon (degarelix) / Astellas, Ferring
Trial completion date, Trial primary completion date: Palifermin With Leuprolide Acetate for the Promotion of Immune Recovery Following Total Body Irradiation Based T-Cell Depleted Allogeneic Hematopoietic Stem Cell Transplantation (clinicaltrials.gov) - Jun 1, 2018
P2, N=93, Recruiting, Sponsor: Memorial Sloan Kettering Cancer Center
Active, not recruiting --> Completed Trial completion date: Dec 2018 --> Dec 2019 | Trial primary completion date: Dec 2018 --> Dec 2019
- | leuprolide acetate for depot suspension / Generic mfg., docetaxel / Generic mfg.
Enrollment closed, Enrollment change, Trial completion date, Trial primary completion date: A Registry for Patients Treated on the Clinical Trial TAX 3503 (clinicaltrials.gov) - Jun 1, 2018
P3, N=52, Active, not recruiting, Sponsor: Memorial Sloan Kettering Cancer Center
Trial completion date: Dec 2018 --> Dec 2019 | Trial primary completion date: Dec 2018 --> Dec 2019 Enrolling by invitation --> Active, not recruiting | N=19 --> 52 | Trial completion date: Mar 2018 --> Mar 2019 | Trial primary completion date: Mar 2018 --> Mar 2019
- | valacyclovir / Generic mfg.
New P2 trial, Combination therapy, Surgery, Gene therapy: Phase II High Risk Prostate Cancer Trial Using Gene & Androgen Deprivation Therapies, Radiotherapy, & Surgery (clinicaltrials.gov) - May 31, 2018
P2, N=60, Not yet recruiting, Sponsor: The Methodist Hospital System
- | Xtandi (enzalutamide capsule) / Pfizer, Astellas
Enrollment closed, Enrollment change: Trial of Radiotherapy With Leuprolide and Enzalutamide in High Risk Prostate Cancer (clinicaltrials.gov) - May 4, 2018
P2, N=11, Active, not recruiting, Sponsor: Hao Nguyen
Enrolling by invitation --> Active, not recruiting | N=19 --> 52 | Trial completion date: Mar 2018 --> Mar 2019 | Trial primary completion date: Mar 2018 --> Mar 2019 Recruiting --> Active, not recruiting | N=53 --> 11
- || Erleada (apalutamide) / J&J
Trial completion date, Trial primary completion date: Apalutamide Plus Intermittent Hormone Therapy Versus Intermittent Hormone Therapy Alone in Prostate Cancer (clinicaltrials.gov) - Apr 30, 2018
P2, N=66, Not yet recruiting, Sponsor: Robert J Amato
Recruiting --> Active, not recruiting | N=53 --> 11 Trial completion date: Dec 2022 --> Dec 2023 | Trial primary completion date: Dec 2021 --> Jul 2022
- | letrozole / Generic mfg.
New P2 trial: NeoChAI: Neo-adjuvant Chemotherapy With Letrozole in Patients With Estrogen Receptor Positive/HER-2 Negative Breast Cancer (clinicaltrials.gov) - Apr 12, 2018
P2, N=114, Recruiting, Sponsor: National Cancer Center, Korea
- | goserelin acetate / Generic mfg., leuprolide acetate for depot suspension / Generic mfg., bicalutamide / Generic mfg.
Trial completion date, Trial primary completion date: CCRO025: Stereotactic Boost and Long-Term Androgen Deprivation for Adenocarcinoma of the Prostate (clinicaltrials.gov) - Apr 11, 2018
P=N/A, N=29, Recruiting, Sponsor: University of California, Davis
Trial completion date: Dec 2022 --> Dec 2023 | Trial primary completion date: Dec 2021 --> Jul 2022 Trial completion date: Mar 2018 --> Oct 2018 | Trial primary completion date: Mar 2018 --> Oct 2018
- | leuprolide acetate for depot suspension / Generic mfg.
Phase classification: A Treatment Study for Premenstrual Syndrome (PMS) (clinicaltrials.gov) - Apr 4, 2018
P, N=100, Recruiting, Sponsor: National Institute of Mental Health (NIMH)
Trial completion date: Mar 2018 --> Oct 2018 | Trial primary completion date: Mar 2018 --> Oct 2018 Phase classification: P=N/A --> P
- | NN1213 / Novo Nordisk
Phase classification: The Effects of Reproductive Hormones on Mood and Behavior (clinicaltrials.gov) - Mar 30, 2018
P, N=150, Recruiting, Sponsor: National Institute of Mental Health (NIMH)
Phase classification: P=N/A --> P Phase classification: P=N/A --> P
- | Xtandi (enzalutamide) / Pfizer, Astellas, Erleada (apalutamide) / J&J
Phase classification, Trial completion date, Trial primary completion date: Micro RNAs to Predict Response to Androgen Deprivation Therapy (clinicaltrials.gov) - Mar 27, 2018
P, N=60, Recruiting, Sponsor: Medical College of Wisconsin
Phase classification: P=N/A --> P Phase classification: P=N/A --> P | Trial completion date: Dec 2020 --> Feb 2022 | Trial primary completion date: Feb 2018 --> Feb 2021
- | Erleada (apalutamide) / J&J
Enrollment open: A Salvage Trial of AR Inhibition With ADT and Apalutamide With Radiation Therapy Followed by Docetaxel in Men With PSA Recurrent Prostate Cancer After Radical Prostatectomy (STARTAR) (clinicaltrials.gov) - Mar 22, 2018
P2, N=42, Recruiting, Sponsor: Tian Zhang, MD
Phase classification: P=N/A --> P | Trial completion date: Dec 2020 --> Feb 2022 | Trial primary completion date: Feb 2018 --> Feb 2021 Not yet recruiting --> Recruiting
- | Erleada (apalutamide) / J&J
Enrollment open: SOLAR: Systemic and Tumor-Directed Therapy for Oligometastatic Prostate Cancer (clinicaltrials.gov) - Mar 13, 2018
P2, N=28, Recruiting, Sponsor: VA Office of Research and Development
Not yet recruiting --> Recruiting Not yet recruiting --> Recruiting
- || leuprolide acetate for depot suspension / Generic mfg.
Trial completion date, Trial primary completion date: CRONOS II: Evaluation of Diet and Exercise in Prostate Cancer Patients (clinicaltrials.gov) - Mar 8, 2018
P=N/A, N=860, Recruiting, Sponsor: AbbVie
Not yet recruiting --> Recruiting Trial completion date: Nov 2020 --> Jul 2021 | Trial primary completion date: Nov 2020 --> Jul 2021
- || leuprolide acetate for depot suspension / Generic mfg.
Enrollment closed: Special Drug Use Surveillance of Leuprorelin for Injection Kit 22.5 mg in "Premenopausal Breast Cancer" (clinicaltrials.gov) - Mar 6, 2018
P=N/A, N=312, Active, not recruiting, Sponsor: Takeda
Trial completion date: Nov 2020 --> Jul 2021 | Trial primary completion date: Nov 2020 --> Jul 2021 Recruiting --> Active, not recruiting
- | docetaxel / Generic mfg.
Trial completion date, Metastases: Docetaxel, Radiation Therapy, and Hormone Therapy in Treating Patients With Locally Advanced Prostate Cancer (clinicaltrials.gov) - Mar 3, 2018
P1, N=20, Active, not recruiting, Sponsor: Medical University of South Carolina
Recruiting --> Active, not recruiting Trial completion date: Dec 2017 --> Dec 2018
- || leuprolide acetate for depot suspension / Generic mfg.
Trial completion date, Trial primary completion date: A Study to Assess the Safety and Efficacy of Enantone (Leuprorelin) in Central Precocious Puberty (CPP) Among Chinese Participants (clinicaltrials.gov) - Feb 28, 2018
P=N/A, N=300, Recruiting, Sponsor: Takeda
Trial completion date: Dec 2017 --> Dec 2018 Trial primary completion date: Feb 2018 --> Sep 2018 | Trial completion date: Feb 2018 --> Sep 2018
- | Menopur (menotropin) / Ferring, Follistim AQ Cartridge (follitropin beta) / Organon, Bravelle (urofollitropin) / Ferring
Enrollment change: Maximal Stimulation and Delayed Fertilization for Diminished Ovarian Reserve: a Randomized Pilot Study (clinicaltrials.gov) - Feb 23, 2018
P4, N=23, Completed, Sponsor: Carolinas Healthcare System
Trial primary completion date: Feb 2018 --> Sep 2018 | Trial completion date: Feb 2018 --> Sep 2018 N=100 --> 23
- | Xtandi (enzalutamide capsule) / Pfizer, Astellas
Enrollment closed, Metastases: LHRH Analogue Therapy With Enzalutamide or Bicalutamide in Treating Patients With Hormone Sensitive Prostate Cancer (clinicaltrials.gov) - Feb 13, 2018
P2, N=92, Active, not recruiting, Sponsor: Barbara Ann Karmanos Cancer Institute
N=100 --> 23 Recruiting --> Active, not recruiting
- | Menopur (menotropin) / Ferring, Orgalutran (ganirelix acetate) / Organon, Follistim AQ Cartridge (follitropin beta) / Organon
Trial completion, Trial primary completion date: Efficacy of Recombinant FSH/GnRH Antagonist Protocol With and Without LH Adjunct for Egg Bank Donation (clinicaltrials.gov) - Feb 13, 2018
P4, N=39, Completed, Sponsor: Michigan Reproductive Medicine
Recruiting --> Active, not recruiting Recruiting --> Completed | Trial primary completion date: Apr 2018 --> Feb 2017
- || Erleada (apalutamide) / J&J
Trial completion date, Trial primary completion date: c15-164: AASUR in High Risk Prostate Cancer (clinicaltrials.gov) - Feb 13, 2018
P2, N=58, Recruiting, Sponsor: Memorial Sloan Kettering Cancer Center
Recruiting --> Completed | Trial primary completion date: Apr 2018 --> Feb 2017 Trial primary completion date: May 2018 --> May 2019 | Trial completion date: May 2018 --> May 2019
- | leuprolide acetate for depot suspension / Generic mfg.
Enrollment change, Trial completion date, Trial initiation date, Trial withdrawal, Trial primary completion date: Treatment of Uterine Fibroids With Magnetic Resonance Guided High Intensity Focused Ultrasound (clinicaltrials.gov) - Feb 6, 2018
P3, N=0, Withdrawn, Sponsor: Thunder Bay Regional Research Institute
Trial primary completion date: May 2018 --> May 2019 | Trial completion date: May 2018 --> May 2019 N=30 --> 0 | Initiation date: Mar 2017 --> Jan 2018 | Not yet recruiting --> Withdrawn | Trial primary completion date: Mar 2019 --> Jan 2018 | Trial completion date: Mar 2020 --> Jan 2018
- | New P4 trial: Aromatase Plus GnRH Analogue Versus GnRH Analog Alone in Adenomyosis (clinicaltrials.gov) - Feb 5, 2018
P4, N=150, Recruiting, Sponsor: Centre for Endocrinology and Reproductive Medicine, Italy
- | cabazitaxel / Generic mfg.
Trial primary completion date: ACDC-RP: Anti-Androgens and Cabazitaxel in Defining Complete Response in Prostatectomy (ACDC Trial) (clinicaltrials.gov) - Feb 1, 2018
P2, N=76, Recruiting, Sponsor: University Health Network, Toronto
N=30 --> 0 | Initiation date: Mar 2017 --> Jan 2018 | Not yet recruiting --> Withdrawn | Trial primary completion date: Mar 2019 --> Jan 2018 | Trial completion date: Mar 2020 --> Jan 2018 Trial primary completion date: Oct 2018 --> Aug 2019
- | Erleada (apalutamide) / J&J
Trial initiation date, Trial primary completion date: A Salvage Trial of AR Inhibition With ADT and Apalutamide With Radiation Therapy Followed by Docetaxel in Men With PSA Recurrent Prostate Cancer After Radical Prostatectomy (STARTAR) (clinicaltrials.gov) - Jan 24, 2018
P2, N=42, Not yet recruiting, Sponsor: Tian Zhang, MD
Trial primary completion date: Oct 2018 --> Aug 2019 Initiation date: Dec 2017 --> Mar 2018 | Trial primary completion date: Dec 2023 --> Mar 2024
- | leuprolide acetate for depot suspension / Generic mfg.
Phase classification, Trial initiation date, Trial primary completion date: Effect of Short Term Ovarian Suppression on Androgen Overproduction in Overweight Girls With Androgen Excess (clinicaltrials.gov) - Jan 23, 2018
P1, N=20, Not yet recruiting, Sponsor: University of Virginia
Initiation date: Dec 2017 --> Mar 2018 | Trial primary completion date: Dec 2023 --> Mar 2024 Phase classification: P=N/A --> P1 | Initiation date: Jun 2017 --> Jun 2018 | Trial primary completion date: Jun 2018 --> Jun 2019
- | Erleada (apalutamide) / J&J
Trial primary completion date: Apalutamide and Leuprolide in Intermediate and High-risk Prostate Cancer (clinicaltrials.gov) - Jan 23, 2018
P2, N=57, Recruiting, Sponsor: Case Comprehensive Cancer Center
Phase classification: P=N/A --> P1 | Initiation date: Jun 2017 --> Jun 2018 | Trial primary completion date: Jun 2018 --> Jun 2019 Trial primary completion date: Oct 2017 --> Dec 2018
- | Ibrance (palbociclib) / Pfizer
Enrollment change, Trial primary completion date, Combination therapy, Metastases: Young-PEARL: A Study of Palbociclib With Exemestane Plus GnRH Versus Capecitabine in Premenopausal Women With HR+ MBC (clinicaltrials.gov) - Jan 17, 2018
P2, N=182, Recruiting, Sponsor: Samsung Medical Center
Trial primary completion date: Oct 2017 --> Dec 2018 N=122 --> 182 | Trial primary completion date: Sep 2019 --> Jun 2021
- | leuprolide acetate for depot suspension / Generic mfg.
Trial completion, Phase classification, Enrollment change, Trial primary completion date: Impact of Hot Flashes on Sleep and Mood Disturbance (clinicaltrials.gov) - Dec 26, 2017
P4, N=29, Completed, Sponsor: Massachusetts General Hospital
N=122 --> 182 | Trial primary completion date: Sep 2019 --> Jun 2021 Active, not recruiting --> Completed | Phase classification: PN/A --> P4 | N=50 --> 29 | Trial primary completion date: Jun 2014 --> Dec 2011
- | leuprolide acetate for depot suspension / Generic mfg.
Trial primary completion date: Pilot Study of Leuprolide to Improve Immune Function After Allogeneic Bone Marrow Transplantation (clinicaltrials.gov) - Dec 11, 2017
P2, N=70, Active, not recruiting, Sponsor: National Cancer Institute (NCI)
Active, not recruiting --> Completed | Phase classification: PN/A --> P4 | N=50 --> 29 | Trial primary completion date: Jun 2014 --> Dec 2011 Trial primary completion date: Dec 2018 --> Nov 2020
- | leuprolide acetate for depot suspension / Generic mfg.
Trial primary completion date: Pilot Study of Leuprolide to Improve Immune Function After Allogeneic Bone Marrow Transplantation (clinicaltrials.gov) - Dec 8, 2017
P2, N=70, Active, not recruiting, Sponsor: National Cancer Institute (NCI)
Trial primary completion date: Dec 2018 --> Nov 2020 Trial primary completion date: Dec 2017 --> Dec 2018
- | leuprolide acetate for depot suspension / Generic mfg.
Trial completion, Enrollment change: Females, Aging, Metabolism, and Exercise (clinicaltrials.gov) - Dec 2, 2017
P=N/A, N=42, Completed, Sponsor: University of Colorado, Denver
Trial primary completion date: Dec 2017 --> Dec 2018 Active, not recruiting --> Completed | N=132 --> 42
- | progesterone / Generic mfg., leuprolide acetate for depot suspension / Generic mfg., estradiol valerate / Generic mfg.
Trial completion, Enrollment change, Trial initiation date, Trial primary completion date: Endometrial Receptivity Profile in Patients With Endometrial Proliferation Defects (clinicaltrials.gov) - Dec 2, 2017
P=N/A, N=1, Completed, Sponsor: Reproductive Medicine Associates of New Jersey
Active, not recruiting --> Completed | N=132 --> 42 Enrolling by invitation --> Completed | N=20 --> 1 | Initiation date: Nov 2014 --> Jul 2015 | Trial primary completion date: Dec 2017 --> Sep 2015
- ||| leuprolide acetate for depot suspension / Generic mfg.
Trial completion: Special Drug Use Surveillance of Leuplin PRO for Injection Kit 22.5 mg for "Prostate Cancer" (clinicaltrials.gov) - Nov 30, 2017
P=N/A, N=300, Completed, Sponsor: Takeda
Enrolling by invitation --> Completed | N=20 --> 1 | Initiation date: Nov 2014 --> Jul 2015 | Trial primary completion date: Dec 2017 --> Sep 2015 Active, not recruiting --> Completed